New combination treatment for advanced head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This study tests a new combination of two drugs—sacituzumab tirumotecan (a targeted therapy) plus an immunotherapy—for people whose head and neck cancer has returned or spread after standard treatment. The goal is to see if this combination can shrink tumors and delay cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 79 years old
- Your head and neck cancer (squamous cell type) has come back or spread and can't be cured with local treatments like surgery or radiation
- You have already tried a standard treatment that included a checkpoint inhibitor (immunotherapy), and your cancer grew or came back during or after that treatment
- You are feeling well enough that you can do most daily activities (ECOG 0 or 1)
- Your blood counts, liver, kidney, and clotting tests are within acceptable ranges, and you haven't needed transfusions or growth factors recently
- You are willing to use effective birth control during the study and for 6 months after the last dose (if you or your partner can become pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
This trial tests a new drug, sacituzumab tirumotecan, in people with advanced thymic carcinoma that has spread or cannot be removed with surgery. It is for those whose cancer has gotten worse after at least one round of platinum-based chemotherapy.
Hear when a new Recurrent or Metastatic Head and Neck Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.